Global Non-Invasive Drug Delivery Devices Market: Analysis and Forecast, 2019-2025

A quick peek into the report

Report Description

Global Non-Invasive Drug Delivery Devices Market by BIS Research projects the market to grow at a significant CAGR of 23.13% durin

Market Report Coverage - Global Non-Invasive Drug Delivery Devices Market
Base Year	2018	Market Size in 2018	$548.5 Million
Forecast Period	2019-2025	Value Estimation by 2025	$ 2354.4 Million
CAGR During Forecast Period	23.13%	Number of Tables	22
Number of Pages	202	Number of Figures	139
Market Segmentation	• Type - needle-free injector and digital respiratory devices • Application - diabetes management, vaccine management, pain management, respiratory management, and others
Regional Segmentation	• North America – U.S. and Canada • Europe – Germany, U.K., France, and Rest-of-Europe • Asia-Pacific – Japan, China, India, Australia, and Rest-of-Asia-Pacific • Latin America, Middle East and Africa
Key Companies Profiled	Novartis AG, Inovio Pharmaceuticals, Inc., Medtronic Plc., Tandem Diabetes Care, Inc., Teva Pharmaceutical Industries Ltd., Crossject Medical Technology, Adherium Ltd., and Sensirion AG, Diabeloop, PharmaJet, PenJet, Portal Instruments, HNS International, Inc., Capsule Technologies, Inc., and Propeller Health, among others.

Market Segmentation

Market Outlook by Type

Presently, the artificial pancreas or closed loop insulin pump devices are the leading contributor to the global non-invasive drug delivery devices market. In 2018, the contribution of the artificial pancreas contributed a significant amount to the total market revenue of the global non-invasive drug delivery devices market. The dominance of artificial pancreas can be attributed to an increasing prevalence of diabetes and the rise in demand for artificial organs.

Non-Invasive Drug Delivery Devices Market

By Region

North America currently holds the largest market share in terms of revenue generation. North America non-invasive drug delivery devices market was valued at $413.4 million in 2018. The increasing burden of chronic diseases, an increase in the prevalence of diabetic population, growing geriatric population, high demand for needle-free injector, and a rise in demand for self-administrable drug delivery devices has resulted in the increased demand for non-invasive drug delivery devices.

The massive demand for such devices is the major factor for propelling the growth of the North America non-invasive drug delivery devices market. However, the non-invasive drug delivery devices market in Europe is anticipated to witness the highest growth rate during the forecast period. The increase in number of prevalence of chronic diseases and high costs associated with the needlestick injuries are driving this market forward during the forecast period.

Key Questions Answered in this Report:

What are the different types of non-invasive drug delivery systems available in the market, and what are the benefits offered by t

Market Overview

The scope of this report is centered upon conducting a detailed study of the non-invasive drug delivery devices used by patients o

Market Overview and Estimation

The global non-invasive drug delivery devices market consists of manufacturers along with the pharmaceutical companies and third-party distributors. The member either operate individually or in partnership to offer non-invasive drug delivery products in the market.

The drug delivery device manufacturers comprises all the market participants that manufacturers non-invasive drug delivery devices for a pharmaceutical company or directly sell them. A drug delivery device manufacturer can have partnerships with more than one pharmaceutical company and thus serve multiple companies.

The pharmaceutical companies manufacture often partner with drug delivery device manufacturers to sell their drugs along with drug delivery devices. In some cases, the pharma companies themselves manufacture the delivery devices as well and sell the combined product that comprises drug and the device as an individual unit.

The global non-invasive drug delivery devices market was valued at $548.5 million in 2018 and is anticipated to reach $2,354.4 million by 2025, witnessing a CAGR of 23.13% in the forecast period 2019-2025. The continued and significant investments by the healthcare companies to meet the industry demand is one of the prominent factors propelling the growth of the global non-invasive drug delivery devices market.

Further, the increasing burden of chronic diseases, an increase in the prevalence of diabetic population, growing geriatric population, high demand for needle-free injector, and a rise in demand for self-administrable drug delivery devices is bolstering the growth of the global non-invasive drug delivery devices market.

Non-Invasive Drug Delivery Devices Industry

Market Dynamics
Growth Drivers	• Increasing Prevalence of Chronic and Lifestyle-Associated Diseases Elevating the Demand of Non-Invasive Drug Delivery Devices • Growing Geriatric Population Leads to Surge in Exigency of Non-Invasive Drug Delivery Devices • Increasing Needlestick Injuries Lead to Surge in Demand of Non-Invasive Drug Delivery Devices • Increasing Demand for the Self-Administered Medication Service • Persistent Support from Government and Non-Government Organizations
Market Restraints	• Technical Barrier to the Non-Invasive Mode of Drug Delivery • Alternative Drug Delivery Technology
Market Opportunities	• Expansion into the Emerging Economies • Technological Advancement of Non-Invasive Drug Delivery Devices • Collaboration between Pharmaceutical Companies and Drug Delivery Firms

Growth Factors

Increasing Prevalence of Chronic and Lifestyle-Associated Diseases: Sedentary lifestyle is leading to growing obesity problems, thus resulting in a massive economic burden of chronic and lifestyle-associated diseases. Globally, mortality rate is increasing due to chronic illness such as stroke, cardiovascular diseases, and chronic neurological conditions, which leads to an increase in demand for non-invasive drug delivery devices. The escalating mortality rate due to chronic and lifestyle-associated diseases has significantly elevated the requirement for non-invasive drug delivery devices for self-administration of drugs.
Growing Geriatric Population: The life expectancy in most of the countries had surged tremendously. The improvement in life expectancy is majorly due to significant advancement in diagnostic technology and medical science and improving awareness regarding health, nutrition, and hygiene. Increasing demand for better treatment facilities with an early diagnosis of chronic diseases surges the demand for advanced treatment facilities.
Increasing Needlestick Injuries: The healthcare providers are exposed to an increased threat of needlestick injuries owing to their exposure to an extremely competitive work environment, which exposes them to enhance the risk of diseases transmitted by the blood, which include tuberculosis, HIV, and hepatitis B-C, among others.
Increasing Demand for the Self-Administered Medication Service: The increasing cos of healthcare is driving the development of the new generation of injectable therapies which can be self-administered by the patient. The growing demand for self-administration has created an immense need for user-friendly drug delivery devices which are safe and efficient. In addition, these devices also boost compliance to therapy throughout various chronic conditions. This mode reduces dependability on any healthcare professional and thus is a suitable treatment option in emergency conditions such as bronchitis and asthma. It could also save time and hospital visits of a patient and will promote the growth of self-administered medication with time.

Download this TOC

Request a Sample

2.1 Research Scope
2.2 Exclusion Criteria of the Report
2.3 Key Questions Answered by the Research Study

3.1 Primary Research

3.2 Secondary Research

3.3 Data Sources Categorization

3.4 Selection Criteria for Company Profiles

3.5 Assumptions and Limitations

4.1 Industry Ecosystem
4.1.1 Drug Delivery Device Manufacturers
4.1.2 Pharmaceutical Companies
4.1.3 Distributors
4.2 Legal and Regulatory Framework
4.3 Voice of Consortium and Associations
4.4 Patent Analysis

5.1 Key Developments and Strategies

5.1.1 Partnerships, Alliances, and Business Expansions

5.1.2 Regulatory and Legal

5.1.3 Merger and Acquisition Activities

5.1.4 New Offerings

5.1.5 Funding Activities

5.1.6 Procurement and Sales

5.2 Market Share Analysis

5.2.1 Market Share Analysis – Needle-Free Injector

5.2.2 Market Share Analysis – Digital Inhalers and Nebulizers

5.3 Price vs. Product Analysis – Needle-Free Injector

5.4 Shelf Life Analysis – Needle-Free Injector

5.5 Pricing Analysis – Digital Inhalers

5.6 Product Portfolio Analysis – Needle-Free Injector

5.7 Product Mapping Analysis – Digital Inhalers and Nebulizers

5.8 Smart Inhaler Value Propositions for Stakeholders

5.9 Smart Inhalers and Nebulizers – An Important Element of System for Predicting Disease Worsening in Individuals

5.10 Business Models for Digital Inhalers and Nebulizers Market

6.1 Assumptions and Limitations
6.2 Market Overview
6.2.1 Advent and Evolution of Drug Delivery
6.2.2 Key Findings and Emerging Trends
6.3 Market Dynamics
6.3.1 Market Drivers
6.3.1.1 Increasing Prevalence of Chronic and Lifestyle-Associated Diseases Elevating the Demand of Non-Invasive Drug Delivery Devices
6.3.1.1.1 Increase in Prevalence of Diabetes Population
6.3.1.1.2 Increase in Prevalence of Neurological Diseases
6.3.1.1.3 Increase in Prevalence of Respiratory Diseases
6.3.1.2 Growing Geriatric Population Leads to Surge in Exigency of Non-Invasive Drug Delivery Devices
6.3.1.3 Increasing Needlestick Injuries Lead to Surge in Demand of Non-Invasive Drug Delivery Devices
6.3.1.4 Increasing Demand for the Self-Administered Medication Service
6.3.1.5 Persistent Support from Government and Non-Government Organizations
6.3.2 Market Restraints
6.3.2.1 Technical Barrier to the Non-Invasive Mode of Drug Delivery
6.3.2.2 Alternative Drug Delivery Technology
6.3.3 Impact Analysis
6.3.4 Market Opportunities
6.3.4.1 Expansion into the Emerging Economies
6.3.4.2 Technological Advancement of Non-Invasive Drug Delivery Devices
6.3.4.2.1 Microneedle Patches for Vaccine Delivery
6.3.4.2.2 Organ-on-Chip
6.3.4.3 Collaboration between Pharmaceutical Companies and Drug Delivery Firms

7.1 Overview
7.2 Artificial Pancreas (Closed-Loop Insulin Pumps)
7.3 Needle-Free Injector
7.3.1 Needle-Free Injector Market (by Technology)
7.3.1.1 Gas-Based Needle-Free Injector
7.3.1.2 Spring-Based Needle-Free Injector
7.3.1.3 Other Needle-Free Injector
7.3.2 Needle-Free Injector Market (by Usability)
7.3.2.1 Reusable Needle-Free Injector
7.3.2.2 Disposable Needle-Free Injector
7.3.3 Needle-Free Injector Market (by Type)
7.3.3.1 Liquid-Based Needle-Free Injector
7.3.3.2 Powder-Based Needle-Free Injector
7.3.4 Needle-Free Injector Market (by Site of Delivery)
7.3.4.1 Subcutaneous Needle-Free Injector
7.3.4.2 Intramuscular Needle-Free Injector
7.3.4.3 Intradermal Needle-Free Injector
7.4 Digital Respiratory Devices
7.4.1 Digital Respiratory Devices Market (by Product Type)
7.4.1.1 Sensors and App
7.4.1.2 Smart Inhalers and Nebulizers

8.1 Overview
8.2 Diabetes Management
8.3 Vaccine Management
8.4 Pain Management
8.5 Respiratory Management
8.6 Others

9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest-of-Asia-Pacific
9.5 Latin America, Middle East and Africa

10.1 Adherium Limited
10.1.1 Company Overview
10.1.2 Role of Adherium Limited in the Global Non-Invasive Drug Delivery Devices Market
10.1.3 Financials
10.1.4 SWOT Analysis
10.2 Capsule Technologies, Inc.
10.2.1 Company Overview
10.2.2 Role of Capsule Technologies, Inc. in the Global Non-Invasive Drug Delivery Devices Market
10.2.3 SWOT Analysis
10.3 Crossject S.A.
10.3.1 Company Overview
10.3.2 Role of Crossject S.A. in the Global Non-Invasive Drug Delivery Devices Market
10.3.3 Financials
10.3.4 SWOT Analysis
10.4 Diabeloop SA
10.4.1 Company overview
10.4.2 Role of Diabeloop SA in the Global Non-Invasive Drug Delivery Devices Market
10.4.3 SWOT Analysis
10.5 HNS International, Inc.
10.5.1 Company Overview
10.5.2 Role of HNS International, Inc. in the Global Non-Invasive Drug Delivery Devices Market
10.5.3 SWOT Analysis
10.6 Inovio Pharmaceuticals, Inc.
10.6.1 Company Overview
10.6.2 Role of Inovio Pharmaceuticals, Inc. in the Global Non-Invasive Drug Delivery Devices Market
10.6.3 Financials
10.6.4 SWOT Analysis
10.7 Medtronic Plc.
10.7.1 Company Overview
10.7.2 Role of Medtronic Plc. in the Non-Invasive Drug Delivery Devices Market
10.7.3 Financials
10.7.4 SWOT Analysis
10.8 Novartis AG
10.8.1 Company Overview
10.8.2 Role of Novartis AG in the Global Non-Invasive Drug Delivery Devices Market
10.8.3 Financials
10.8.4 SWOT Analysis
10.9 PenJet Corporation
10.9.1 Company Overview
10.9.2 Role of PenJet in the Global Non-Invasive Drug Delivery Devices Market
10.9.3 SWOT Analysis
10.10 PharmaJet
10.10.1 Company Overview
10.10.2 Role of Pharma Jet in the Global Non-Invasive Drug Delivery Devices Market
10.10.3 SWOT Analysis
10.11 Portal Instruments
10.11.1 Company Overview
10.11.2 Role of Portal Instruments in the Global Non-Invasive Drug Delivery Devices Market
10.11.3 SWOT Analysis
10.12 Propeller Health (A Subsidiary of ResMed)
10.12.1 Company Overview
10.12.2 Role of Propeller Health in the Global Non-Invasive Drug Delivery Devices Market
10.12.3 SWOT Analysis
10.13 Sensiron AG
10.13.1 Company Overview
10.13.2 Role of Sensiron AG in the Global Non-Invasive Drug Delivery Devices Market
10.13.3 Financials
10.13.4 SWOT Analysis
10.14 Tandem Diabetes Care, Inc.
10.14.1 Company Overview
10.14.2 Role of Tandem Diabetes Care, Inc. in the Global Non-Invasive Drug Delivery Devices Market
10.14.3 Financials
10.14.4 SWOT Analysis
10.15 Teva Pharmaceuticals Industries Ltd.
10.15.1 Company Overview
10.15.2 Role of Teva Pharmaceuticals Industries Ltd. in the Global Non-Invasive Drug Delivery Devices Market
10.15.3 Financials
10.15.4 SWOT Analysis

Table 4.1: Regulatory Authority of the Global Non-Invasive Drug Delivery Devices Market
Table 4.2: Association/ Society/ Consortium of the Global Non-Invasive Drug Delivery Devices Market
Table 5.1: Product Portfolio Analysis – Needle Free Injector
Table 5.2: Product Portfolio Analysis – Digital Inhalers and Nebulizers
Table 5.3: Different Data Revenue Streams
Table 6.1: Deaths due to Multiple Sclerosis in Key Countries, 2015-2017
Table 6.2: Prevalence of Asthma in Key Countries, 2015-2017
Table 6.3: Prevalence of COPD in Key Countries, 2015-2017
Table 6.4: Funding Initiatives by Government and Research Institutes
Table 6.5: Funding Initiatives by Public and Private Companies
Table 9.1: Prevalence of Diseases in North America, 2014-2017
Table 9.2: Prevalence of Diseases in the U.S., 2014-2017
Table 9.3: Prevalence of Diseases in Canada, 2014-2017
Table 9.4: Prevalence of Diseases in Europe, 2014-2017
Table 9.5: Prevalence of Diseases in Germany, 2014-2017
Table 9.6: Prevalence of Diseases in the U.K., 2014-2017
Table 9.7: Prevalence of Diseases in France, 2014-2017
Table 9.8: Prevalence of Diseases in Asia, 2014-2017
Table 9.9: Prevalence of Diseases in Japan, 2014-2017
Table 9.10: Prevalence of Diseases in China, 2014-2017
Table 9.11: Prevalence of Diseases in India, 2014-2017
Table 9.12: Prevalence of Diseases in Australia, 2014-2017

Figure 1: Number of People (20-79 years) with Diabetes in 2017 and 2045
Figure 2: Global Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 3: Market Drivers and Market Restraints
Figure 4: Market Share Analysis – Needle-Free Injector (by Company), 2018
Figure 5: Market Share Analysis – Digital Inhalers and Nebulizers (by Company), 2018
Figure 6: Partnerships, Alliances, and Business Expansions Share (by Company), March 2015-March 2020
Figure 7: Global Non-Invasive Drug Delivery Devices Market (by Type), 2018 and 2025
Figure 8: Global Non-Invasive Drug Delivery Devices Market (by Region), 2018 and 2025
Figure 9: Share of Patent by Ownership, January 2016-December 2019
Figure 2.1: Global Non-Invasive Drug Delivery Devices Market Segmentation
Figure 3.1: Global Non-Invasive Drug Delivery Devices Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Total Number of Companies Profiles
Figure 3.5: Assumptions and Limitations
Figure 4.1: Share of Patent by Ownership, January 2016-December 2019
Figure 5.1: Share of Key Developments and Strategies, March 2015-March 2020
Figure 5.2: Partnerships, Alliances, and Business Expansions Share (by Company), March 2015-March 2020
Figure 5.3: Regulatory and Legal (by Company), March 2015-March 2020
Figure 5.4: Merger and Acquisition Activities (by Company), March 2015-March 2020
Figure 5.5: New Offerings Share (by Company), March 2015-March 2020
Figure 5.6: Fundings Share (by Company), March 2015-March 2020
Figure 5.7: Procurement and Sales (by Company), March 2015-March 2020
Figure 5.8: Market Share Analysis – Needle-Free Injector (by Company), 2018
Figure 5.9: Market Share Analysis – Digital Inhalers and Nebulizers (by Company), 2018
Figure 5.10: Price vs. Product Analysis – Needle-Free Injector
Figure 5.11: Shelf Life Analysis – Needle-Free Injector
Figure 5.12: Pricing Analysis – Digital Inhalers
Figure 5.13: Smart Inhaler Value Propositions for Stakeholders
Figure 5.14: Smart Inhalers and Nebulizers – An Important Element of System for Predicting Disease Worsening in Individuals
Figure 6.1: Emergence of Needle-Free Technology
Figure 6.2: Number of People (20-79 years) with Diabetes in 2017, and 2045
Figure 6.3: Geriatric Population (60 years and above) Worldwide in Different Regions, 2000, 2015, 2030, and 2050
Figure 6.4: Impact Analysis
Figure 7.1: Global Non-Invasive Drug Delivery Devices Market, (by Type), 2018 and 2025
Figure 7.2: Drivers and Restraints for the Artificial Pancreas Market
Figure 7.3: Global Artificial Pancreas Market, 2018-2025
Figure 7.4: Drivers and Restraints for the Needle-Free Injectors Market
Figure 7.5: Global Needle-Free Injector Market, 2018-2025
Figure 7.6: Segmentation of Needle-Free Injector Market (by Technology)
Figure 7.7: Global Needle-Free Injector Market (by Technology), 2018 and 2025
Figure 7.8: Global Gas-Based Needle-Free Injector Market, 2018-2025
Figure 7.9: Global Spring-Based Needle-Free Injector Market, 2018-2025
Figure 7.10: Global Other Needle-Free Injector Market, 2018-2025
Figure 7.11: Segmentation of Needle-Free Injector Market (by Usability)
Figure 7.12: Global Needle-free Injector Market (by Usability), 2018 and 2025
Figure 7.13: Global Reusable Needle-Free Injector Market, 2018-2025
Figure 7.14: Global Disposable Needle-Free Injector Market, 2018-2025
Figure 7.15: Segmentation of Needle-Free Injector Market (by Type)
Figure 7.16: Global Needle-Free Injector Market (by Type), 2018 and 2025
Figure 7.17: Global Liquid-Based Needle-Free Injector Market, 2018-2025
Figure 7.18: Global Powder-Based Needle-Free Injector Market, 2018-2025
Figure 7.19: Segmentation of Needle-Free Injector Market (by Site of Delivery)
Figure 7.20: Global Needle-Free Injector Market (by Site of Delivery), 2018 and 2025
Figure 7.21: Global Subcutaneous Needle-Free Injector Market, 2018-2025
Figure 7.22: Global Intramuscular Needle-Free Injector Market, 2018-2025
Figure 7.23: Global Intradermal Needle-Free Injector Market, 2018-2025
Figure 7.24: Drivers and Restraints for the Digital Respiratory Devices Market
Figure 7.25: Global Digital Respiratory Devices Market, 2018-2025
Figure 7.26: Segmentation of Digital Respiratory Devices Market (by Product Type)
Figure 7.27: Global Digital Respiratory Devices Market, by Sensor and App, 2018-2025
Figure 7.28: Global Digital Respiratory Devices Market, (by Digital Respiratory Devices), 2018-2025
Figure 8.1: Global Non-Invasive Drug Delivery Devices Market for Diabetes Management, 2018-2025
Figure 8.2: Global Non-Invasive Drug Delivery Devices Market for Vaccine Management, 2018-2025
Figure 8.3: Global Non-Invasive Drug Delivery Devices Market for Pain Management, 2018-2025
Figure 8.4: Global Non-Invasive Drug Delivery Devices Market for Respiratory Management, 2018-2025
Figure 8.5: Global Non-Invasive Drug Delivery Devices Market for Others, 2018-2025
Figure 9.1: Global Non-Invasive Drug Delivery Devices Market Scenario, 2018 to 2025
Figure 9.2: North America Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.3: North America: Market Dynamics
Figure 9.4: U.S. Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.5: Canada Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.6: Europe Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.7: Europe: Market Dynamics
Figure 9.8: Germany Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.9: U.K. Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.10: France Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.11: Rest-of-Europe Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.12: Asia-Pacific Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.13: Asia-Pacific: Market Dynamics
Figure 9.14: Japan Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.15: China Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.16: India Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.17: Australia Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.18: Rest-of-Asia-Pacific Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.19: Latin America, Middle East and Africa Non-Invasive Drug Delivery Devices Market, 2018-2025
Figure 9.20: Latin America, Middle East and Africa: Market Dynamics
Figure 10.1: Adherium Limited: Product Offerings
Figure 10.2: Overall Financials, 2016-2018
Figure 10.3: R&D Expense, 2016-2018
Figure 10.4: Adherium Limited: SWOT Analysis
Figure 10.5: Capsule Technologies, Inc.: Product Offerings
Figure 10.6: Capsule Technologies, Inc.: SWOT Analysis
Figure 10.7: Crossject S.A.: Product Offerings
Figure 10.8: Overall Financials, 2017-2019
Figure 10.9: Crossject S.A.: SWOT Analysis
Figure 10.10: Diabeloop SA: Product Offerings
Figure 10.11: Diabeloop SA : SWOT Analysis
Figure 10.12: HNS International, Inc.: Product Offerings
Figure 10.13: HNS International, Inc.: SWOT Analysis
Figure 10.14: Inovio Pharmaceuticals, Inc.: Product Offerings
Figure 10.15: Inovio Pharmaceuticals, Inc.: Overall Financials, 2017-2019
Figure 10.16: Inovio Pharmaceuticals, Inc.: R& D Expense, 2017-2019
Figure 10.17: Inovio Pharmaceuticals, Inc.: SWOT Analysis
Figure 10.18: Medtronic Plc.: Product Portfolio
Figure 10.19: Medtronic Plc.: Overall Financials, 2017-2019
Figure 10.20: Medtronic Plc.: Revenue (by Segment), 2017-2019
Figure 10.21: Medtronic Plc.: Revenue (by Region), 2017-2019
Figure 10.22: Medtronic Plc.: Research and Development Expense, 2017-2019
Figure 10.23: Medtronic Plc.: SWOT Analysis
Figure 10.24: Novartis AG: Product Offerings
Figure 10.25: Novartis AG: Overall Financials, 2017-2019
Figure 10.26: Novartis AG Net Revenue (by Business Segment), 2016-2018
Figure 10.27: Novartis AG: Net Revenue (by Region), 2016-2018
Figure 10.28: Novartis AG: R&D Expense, 2016-2018
Figure 10.29: Novartis AG: SWOT Analysis
Figure 10.30: PenJet: Product Offerings
Figure 10.31: PenJet :SWOT Analysis
Figure 10.32: Pharma Jet: Product Offerings
Figure 10.33: PharmaJet: SWOT Analysis
Figure 10.34: Portal Instruments: Product Offerings
Figure 10.35: Portal Instruments: SWOT Analysis
Figure 10.36: Propeller Health: Product Offerings
Figure 10.37: Propeller Health: SWOT Analysis
Figure 10.38: Sensirion AG: Product Offerings
Figure 10.39: Sensirion AG: Overall Financials, 2017-2019
Figure 10.40: Sensirion AG: Net Revenue (by Business Segment), 2017-2019
Figure 10.41: Sensirion AG: Net Revenue (by Region), 2017-2019
Figure 10.42: Sensirion AG: R&D Expense, 2017-2019
Figure 10.43: Sensirion AG: SWOT Analysis
Figure 10.44: Tandem Diabetes Care, Inc.: Overall Product Offerings
Figure 10.45: Tandem Diabetes Care, Inc.: Overall Financials, 2016-2018
Figure 10.46: Tandem Diabetes Care, Inc.: Research and Development Expense, 2017-2019
Figure 10.47: Tandem Diabetes Care, Inc.: SWOT Analysis
Figure 10.48: Teva Pharmaceuticals Industries Ltd.: Overall Product Offerings
Figure 10.49: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2016-2018
Figure 10.50: Teva Pharmaceuticals Industries Ltd.: Net Revenue (by Business Segment), 2016-2018
Figure 10.51: Teva Pharmaceuticals Industries Ltd.: Research and Development Expense, 2016-2018
Figure 10.52: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis